X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (9324) 9324
Book Review (2059) 2059
Publication (638) 638
Newsletter (73) 73
Book Chapter (46) 46
Conference Proceeding (25) 25
Book / eBook (7) 7
Magazine Article (7) 7
Dissertation (6) 6
Newspaper Article (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (8449) 8449
humans (6411) 6411
animals (3953) 3953
male (2504) 2504
female (2179) 2179
plasminogen-activator (1550) 1550
mice (1320) 1320
peripheral vascular disease (1184) 1184
biochemistry & molecular biology (1148) 1148
middle aged (1113) 1113
hematology (1104) 1104
abridged index medicus (1091) 1091
rats (1039) 1039
fibrinolysis (944) 944
cells, cultured (908) 908
aged (845) 845
adult (824) 824
expression (783) 783
urokinase-type plasminogen activator - antagonists & inhibitors (782) 782
plasminogen-activator inhibitor-1 (759) 759
pharmacology & pharmacy (726) 726
cardiac & cardiovascular systems (716) 716
tissue-plasminogen activator (702) 702
oncology (699) 699
thrombolytic therapy (699) 699
urokinase-type plasminogen activator - metabolism (694) 694
tissue plasminogen activator (692) 692
cell biology (675) 675
stroke (673) 673
neurosciences (654) 654
time factors (607) 607
thrombolysis (597) 597
research (574) 574
fibrinolytic agents - therapeutic use (569) 569
plasminogen activators - antagonists & inhibitors (560) 560
tissue plasminogen activator - therapeutic use (528) 528
plasminogen inactivators (509) 509
dose-response relationship, drug (505) 505
urokinase (502) 502
disease models, animal (501) 501
acute myocardial-infarction (495) 495
fibrinolysis - drug effects (485) 485
plasminogen activator inhibitor 1 - metabolism (483) 483
analysis (472) 472
treatment outcome (471) 471
cancer (466) 466
fibrinolysin - antagonists & inhibitors (464) 464
inflammation (453) 453
risk factors (444) 444
kinetics (441) 441
in-vivo (437) 437
proteins (429) 429
endothelial-cells (423) 423
cell line, tumor (421) 421
tissue-plasminogen-activator (420) 420
plasminogen activator inhibitor 1 - genetics (417) 417
signal transduction (417) 417
clinical neurology (414) 414
tissue plasminogen activator - metabolism (405) 405
thrombosis (403) 403
angiogenesis (402) 402
care and treatment (396) 396
health aspects (394) 394
metastasis (386) 386
plasminogen - metabolism (380) 380
receptor (379) 379
physiological aspects (377) 377
molecular sequence data (375) 375
tissue plasminogen activator - antagonists & inhibitors (375) 375
cells (372) 372
therapy (369) 369
in-vitro (362) 362
gene expression (360) 360
cell line (358) 358
gene-expression (357) 357
receptors, urokinase plasminogen activator (357) 357
amino acid sequence (356) 356
myocardial infarction - drug therapy (355) 355
article (354) 354
ischemia (352) 352
plasminogen (352) 352
tumor cells, cultured (350) 350
medicine & public health (343) 343
thrombin (337) 337
rna, messenger - metabolism (332) 332
drug therapy (327) 327
endocrinology & metabolism (325) 325
enzyme inhibitors - pharmacology (324) 324
mice, inbred c57bl (320) 320
myocardial-infarction (315) 315
rats, sprague-dawley (312) 312
drug therapy, combination (307) 307
urokinase-type plasminogen activator - genetics (301) 301
invasion (298) 298
protein binding (298) 298
medicine, research & experimental (297) 297
stroke - drug therapy (293) 293
apoptosis (292) 292
binding (292) 292
plasminogen activators - metabolism (292) 292
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9152) 9152
Russian (66) 66
German (54) 54
French (49) 49
Japanese (48) 48
Chinese (22) 22
Polish (17) 17
Spanish (15) 15
Italian (7) 7
Korean (4) 4
Dutch (3) 3
Finnish (2) 2
Swedish (2) 2
Czech (1) 1
Hebrew (1) 1
Hungarian (1) 1
Serbian (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
American Heart Journal, ISSN 0002-8703, 2016, Volume 182, pp. 28 - 35
Background Non-vitamin K antagonist oral anticoagulants (NOACs, dabigatran, rivaroxaban, apixaban, and edoxaban) have been increasingly used as alternatives to... 
Cardiovascular | INTRAVENOUS THROMBOLYSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | DABIGATRAN ANTICOAGULATION | TISSUE-PLASMINOGEN ACTIVATOR | WARFARIN | ACUTE ISCHEMIC-STROKE | GUIDELINES | INTRACEREBRAL HEMORRHAGE | RISK SCORE | HEALTH-CARE PROFESSIONALS | INTRACRANIAL HEMORRHAGE | United States - epidemiology | Dabigatran - adverse effects | Dabigatran - administration & dosage | Anticoagulants - administration & dosage | Humans | Stroke - diagnosis | Warfarin - adverse effects | Male | Thiazoles - administration & dosage | Antithrombins - administration & dosage | Medication Therapy Management - standards | Warfarin - administration & dosage | Rivaroxaban - administration & dosage | Thiazoles - adverse effects | Pyridones - administration & dosage | Pyridines - adverse effects | Rivaroxaban - adverse effects | Adult | Female | Registries | Stroke - therapy | Pyrazoles - adverse effects | Stroke - prevention & control | Pyridines - administration & dosage | Administration, Oral | Atrial Fibrillation - drug therapy | Atrial Fibrillation - complications | Emergency Treatment - methods | Anticoagulants - adverse effects | Outcome and Process Assessment (Health Care) | Pyrazoles - administration & dosage | Stroke - etiology | Quality Improvement | Antithrombins - adverse effects | Emergency Treatment - mortality | Pyridones - adverse effects | Cohort Studies | Stroke (Disease) | Warfarin | Diet therapy | Stroke patients | Atrial fibrillation | Index Medicus | Abridged Index Medicus
Journal Article
ChemMedChem, ISSN 1860-7179, 11/2017, Volume 12, Issue 21, pp. 1794 - 1809
Tight protein–protein interactions ( K d <100 n m ) that occur over a large binding interface (>1000 Å 2 ) are highly challenging to disrupt with small... 
protein–protein interactions | urokinase receptor | virtual screening | small molecules | CHEMISTRY, MEDICINAL | DISCOVERY | protein-protein interactions | SCREENING LIBRARIES | PERCEPTION | PLASMINOGEN-ACTIVATOR | GENERALIZED BORN | PHARMACOLOGY & PHARMACY | OPTIMIZATION | INHIBITORS | BINDING | RATIONAL DESIGN | Protein Structure, Tertiary | Small Molecule Libraries - pharmacology | Urokinase-Type Plasminogen Activator - antagonists & inhibitors | Enzyme-Linked Immunosorbent Assay | Protein Interaction Domains and Motifs - drug effects | Humans | Small Molecule Libraries - metabolism | Structure-Activity Relationship | Receptors, Urokinase Plasminogen Activator - antagonists & inhibitors | Receptors, Urokinase Plasminogen Activator - metabolism | Small Molecule Libraries - chemistry | Thermodynamics | High-Throughput Screening Assays | Urokinase-Type Plasminogen Activator - metabolism | Inhibitory Concentration 50 | Molecular Docking Simulation | Kinetics | Binding Sites | Protein-protein interactions | Binding | Residues | Inhibitor drugs | Test procedures | Antagonists | Pharmacology | Mimicry | U-Plasminogen activator | Proteins | Urokinase | Inhibitors | Historical account | Ligands | Libraries | Protein interaction | Binding sites | Index Medicus | Virtual screening | Small molecule | Protein-protein interaction | Urokinase receptor
Journal Article
Scientific Reports, ISSN 2045-2322, 12/2017, Volume 7, Issue 1, pp. 1312 - 17
Journal Article
ACS Chemical Biology, ISSN 1554-8929, 06/2015, Volume 10, Issue 6, pp. 1521 - 1534
The urokinase receptor (uPAR) is a GPI-anchored cell surface receptor that is at the center of an intricate network of protein-protein interactions. Its... 
Focal Adhesion Kinase 1 - genetics | Integrin alphaVbeta3 - chemistry | Small Molecule Libraries - pharmacology | Urokinase-Type Plasminogen Activator - antagonists & inhibitors | Humans | Integrins - genetics | Vitronectin - genetics | Integrins - metabolism | Vitronectin - antagonists & inhibitors | Integrin alphaVbeta3 - metabolism | Thermodynamics | Integrin alphaVbeta3 - genetics | HEK293 Cells | Urokinase-Type Plasminogen Activator - chemistry | Binding Sites | Focal Adhesion Kinase 1 - metabolism | Serine Proteinase Inhibitors - pharmacology | Integrin alphaVbeta3 - antagonists & inhibitors | Binding, Competitive | Cell Survival - drug effects | Receptors, Urokinase Plasminogen Activator - chemistry | Serine Proteinase Inhibitors - chemical synthesis | Signal Transduction | Gene Expression Regulation | Small Molecule Libraries - chemical synthesis | Urokinase-Type Plasminogen Activator - genetics | Cell Adhesion - drug effects | Vitronectin - metabolism | Receptors, Urokinase Plasminogen Activator - antagonists & inhibitors | Peptides - pharmacology | Receptors, Urokinase Plasminogen Activator - metabolism | Cell Movement - drug effects | Pyrroles - pharmacology | Pyrroles - chemical synthesis | Urokinase-Type Plasminogen Activator - metabolism | Vitronectin - chemistry | Cell Line, Tumor | Protein Binding | Receptors, Urokinase Plasminogen Activator - genetics | Kinetics | rac1 GTP-Binding Protein - metabolism | Receptor Cross-Talk - drug effects | rac1 GTP-Binding Protein - genetics | Index Medicus
Journal Article
American Heart Journal, ISSN 0002-8703, 2006, Volume 152, Issue 1, pp. 125.e1 - 125.e8
Journal Article
Journal Article
Circulation, ISSN 0009-7322, 03/2017, Volume 135, Issue 11, pp. 1024 - 1035
BACKGROUND:Intravenous rt-PA (recombinant tissue-type plasminogen activator) is effective in improving outcomes in ischemic stroke; however, there are few data... 
thrombolysis, therapeutic | anticoagulant agents | intracranial hemorrhages | stroke, acute | CARDIAC & CARDIOVASCULAR SYSTEMS | DABIGATRAN ANTICOAGULATION | PERFORMANCE | GUIDELINES | RISK SCORE | HEALTH-CARE PROFESSIONALS | INTRACRANIAL HEMORRHAGE | therapeutic | EARLY MANAGEMENT | WARFARIN | HEART-ASSOCIATION | thrombolysis | PERIPHERAL VASCULAR DISEASE | Recombinant Proteins - therapeutic use | Pyrazoles - therapeutic use | Tissue Plasminogen Activator - metabolism | Humans | Male | Tissue Plasminogen Activator - therapeutic use | Recombinant Proteins - biosynthesis | Tissue Plasminogen Activator - genetics | Dabigatran - therapeutic use | Warfarin - therapeutic use | Recombinant Proteins - isolation & purification | Time Factors | Fibrinolytic Agents - therapeutic use | Hemorrhage - etiology | Aged, 80 and over | Female | Registries | Retrospective Studies | Stroke - mortality | Rivaroxaban - therapeutic use | Hospital Mortality | Risk Factors | Anticoagulants - therapeutic use | Treatment Outcome | Stroke - drug therapy | International Normalized Ratio | Administration, Intravenous | Aged | Pyridones - therapeutic use | Stroke (Disease) | Treatment outcome | Care and treatment | Usage | Tissue plasminogen activator | Analysis | Dosage and administration | Thrombolytic therapy | Index Medicus | Abridged Index Medicus
Journal Article
British Journal of Pharmacology, ISSN 0007-1188, 08/2015, Volume 172, Issue 15, pp. 3904 - 3916
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 04/2019, Volume 129, Issue 4, pp. 1713 - 1726
Soluble urokinase receptor (suPAR) is a circulatory molecule that activates αvβ3 integrin on podocytes, causes foot process effacement, and contributes to... 
Nephrology | Chronic kidney disease | Integrins | Pathogenesis | Arthritis | Inflammation | Glycine | U-Plasminogen activator | Proteins | Arginine | Biopsy | Morphology | Rodents | ICOS protein | Bone marrow | Tumor necrosis factor-TNF | Ligands | Affinity | Diabetes | Kidney diseases | Proteinuria
Journal Article